Challenges in IBD Research: Precision Medicine

Denson, Lee A.; Curran, Mark; McGovern, Dermot; Koltun, Walter A.; Duerr, Richard H.; Kim, Sandra C.; Sartor, R. Balfour; Sylvester, Francisco; Abraham, Clara; Zoeten, Edwin F. de; Siegel, Corey A.; Burns, Richéal; Dobes, Angela; Shtraizent, Nataly; Honig, Gerard; Heller, Caren; Hurtado-Lorenzo, Andrés; Cho, Judy H.

doi:10.1093/ibd/izz078

Cited by 71 publications

(55 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The concept of precision medicine in inflammatory bowel diseases (IBD) points out to the use of a specific drug to a single patient, at a determinate time, that can confer the highest chance of controlling disease activity, by inducing clinical, biological, endoscopic and/or histologic response or remission. 25 In clinical practice, precision medicine could be classified in 2 phases. The first phase, which ideally should be pretreatment, refers to the choice of which drug to use.…”

Section: Tdm In Ibd: Concepts and Applicationsmentioning

confidence: 99%

Correlation of serum levels of anti-tumor necrosis factor agents with perianal fistula healing in Crohn’s disease: a narrative review

2021

View full text Add to dashboard Cite

overall CD patients 3 and more than 90% of patients with rectal involvement. 4 The management of PFCD is multidisciplinary, with intensive medical therapy associated to multiple surgical procedures. This usually results in significant physical and psychological impact in patients' lives. There are significant limitations of conventional medical treatment in PFCD (corticosteroids, immunosuppressants, and antibiotics). Fistula healing rates are low with this strategy and recurrence is frequent. 5 Some prospective studies have demonstrated the efficacy of biologics in controlling perianal fistulas in CD. Present et al., 6 in the first randomized controlled study with biologics for the treatment of fistulizing CD, demonstrated the effectiveness of infliximab (IFX) in closing abdominal and perianal fistulas. Sands et al., 7 in the ACCENT 2 study, demonstrated the better efficacy of IFX as compared to

show abstract

Section: Tdm In Ibd: Concepts and Applicationsmentioning

confidence: 99%

Correlation of serum levels of anti-tumor necrosis factor agents with perianal fistula healing in Crohn’s disease: a narrative review

2021

View full text Add to dashboard Cite

show abstract

“…As more and more new therapies are put in clinical practice, precision medicine will become a vital challenge for IBD treatment. This involves accurate stratification of patients, the use of effective and reliable biomarkers, and the determination of the optimal clinical pathways for different individuals (19).…”

Section: Introductionmentioning

confidence: 99%

Serum Biomarkers for Inflammatory Bowel Disease

et al. 2020

View full text Add to dashboard Cite

Background: Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a chronic, inflammatory disorder of the gastrointestinal tract. As the novel therapeutic goal and biologicals are widely recognized, accurate assessment of disease and prediction of therapeutic response have become a crucial challenge in clinical practice. Also, because of the continuously rising incidence, convenient and economical methods of diagnosis and clinical assessment are urgently needed. Recently, serum biomarkers have made a great progress and become a focus in IBD study because they are non-invasive, convenient, and relatively inexpensive than are markers in biopsy tissue, stool, breath, and other body fluids. Aims: To review the available data on serological biomarkers for IBD. Methods: We searched PubMed using predefined key words on relevant literatures of serum biomarkers regarding diagnosis, evaluation of therapeutic efficacy, surveillance of disease activity, and assessment of prognosis for IBD. Results: We reviewed serological biomarkers that are well-established and widely used (e.g., C-reactive protein), newly discovered biomarkers (e.g., cytokines, antibodies, and non-coding RNAs), and also recently advancements in serological biomarkers (e.g., metabolomics and proteomics) that are used in different aspects of IBD management. Conclusions: With such a wealth of researches, to date, there are still no ideal serum biomarkers for IBD. Serum profiling and non-coding RNAs are just starting to blossom but reveal great promise for future clinical practice. Combining different biomarkers can be valuable in improving performance of disease evaluation.

show abstract

“…The mitochondria and UC Recent progress has been driven by a strong focus on direct studies on the inflamed mucosa specifically in newly diagnosed or drug-naïve individuals 38,100,101 . Of interest, using a bulk RNAseq approach in 206 newly diagnosed paediatric UC individuals (PROTECT study), Haberman et al showed a significant reduction in the expression of mitochondrial genes that encode the oxidative phosphorylation chain (responsible for energy production) and nuclear encoded genes such as PPARGC1A (responsible for mitochondrial biogenesis), implicating mitochondriopathy as a pathogenic process in UC 100 .…”

Section: New Progress In the Pathogenesis Of Ucmentioning

confidence: 99%

Ulcerative colitis: Recent advances in the understanding of disease pathogenesis

2020

View full text Add to dashboard Cite

Inflammatory bowel diseases are common, complex, immune-mediated conditions with a sharply rising global prevalence. While major advances since 2000 have provided strong mechanistic clues implicating a de-regulation in the normal interaction among host genetics, immunity, microbiome, and the environment, more recent progress has generated entirely new hypotheses and also further refined older disease concepts. In this review, we focus specifically on these novel developments in the pathogenesis of ulcerative colitis.

show abstract

Challenges in IBD Research: Precision Medicine

Cited by 71 publications

References 31 publications

Correlation of serum levels of anti-tumor necrosis factor agents with perianal fistula healing in Crohn’s disease: a narrative review

Correlation of serum levels of anti-tumor necrosis factor agents with perianal fistula healing in Crohn’s disease: a narrative review

Serum Biomarkers for Inflammatory Bowel Disease

Ulcerative colitis: Recent advances in the understanding of disease pathogenesis

Contact Info

Product

Resources

About